Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502800 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of ARQ 761 in Advanced Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 1
- Study location
NCT01502800 is a Phase 1 study of Solid Tumors that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 91 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01502800, a Phase 1 study of Solid Tumors, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 761 administered intravenously. Secondary Objectives: To determine the pharmacokinetic profile of ARQ 761 To assess the preliminary anti-tumor activity of aRQ 761
Conditions Studied
Interventions
- DRUG ARQ 761
- DRUG ARQ 761 Weekly Administration
- DRUG Bi-Weekly Administration of ARQ 761
- DRUG Two Consecutive Weeks Administration of ARQ 761 with one week of rest
Study Locations (1)
Texas
- UT Southwestern Medical Center - Simmons Cancer Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2011-12-29 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01502800
The ClinicalTrials.gov registry entry for NCT01502800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (68% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which ARQ 761 is the first listed.
NCT01502800 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01502800 about?
NCT01502800 is a clinical study titled "Clinical Trial of ARQ 761 in Advanced Solid Tumors". Primary Objective: To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 761 administered intravenously. Secondary Objectives: To determine the pharmacokinetic profile of ARQ 761 To assess the preliminary anti-tumor activity of aRQ 761
What is the current status of trial NCT01502800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2011-12-29. Estimated completion is 2019-03.
What conditions does trial NCT01502800 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT01502800?
The interventions under investigation include: ARQ 761 (DRUG), ARQ 761 Weekly Administration (DRUG), Bi-Weekly Administration of ARQ 761 (DRUG), Two Consecutive Weeks Administration of ARQ 761 with one week of rest (DRUG).
Who is sponsoring clinical trial NCT01502800?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01502800 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.